Shares of ALX Oncology Holdings Inc. (ALXO) were trading up over 114 percent on Tuesday after the company reported positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial of Evorpacept for Cancer.
Immuno-oncology company ALX Oncology Holdings Inc. (ALXO) announced Tuesday positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company's CD47 blocking therapeutic, in combination with trastuzumab, CYRAMZA (ramucirumab) and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction (GEJ) cancer.